|Day Low/High||1.89 / 2.05|
|52 Wk Low/High||0.64 / 5.37|
Shares of insulin maker Mannkind plummeted on news of a proposed stock split, staffing changes and a new iteration of its insulin.
Mannkind stock is suffering, and the company appears to be in trouble.
Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.
The stock has taken a beating, but users of Afrezza are loyal to the drug.
2016 tweets by TheStreet's Adam Feuerstein kept us informed and entertained. From an unexpected twist on New Year's day with MannKind to J.P. Morgan's Healthcare conference to Bristol-Myers Squibb's oops!
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
Donald Trump's victory may be a win for Wall Street traders; Colgate-Palmolive remains on slippery slope; and more from TheStreet and its various properties.
MannKind bulls -- the rainbow-hued unicorns of the investment world -- believe the company's marketing efforts will succeed. They're wrong.
- Conference Call to Begin Today at 5:00 PM ET -
Our screen reveals 17 names that could become oversold and disconnected from their fundamentals as a result of this phenomenon.
Investors in MannKind Corp saw new options begin trading this week, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new December 16th contracts and identified the following put contract of particular interest.
In trading on Friday, shares of MannKind Corp touched a new 52-week low of $0.61/share. That's a $3.18 share price drop, or -83.91% decline from the 52-week high of $3.79 set back on 10/28/2015.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in MannKind Corp , where a total of 77,659 contracts have traded so far, representing approximately 7.8 million underlying shares. That amounts to about 183% of MNKD's average daily trading volume over the past month of 4.2 million shares.
These under-$10 stocks look ready to break out and trade higher from current levels.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.